

93
4-5-99
WO
PALM INTRANET9*31
Day : Saturday
Date: 5/22/1999
Time: 13:46:58**PUBS Application Status Query for 08/466343****View Work Flow Content**

Search Another: Serial Number

 Search

Class/Subclass : 435/069.100

Status : 093/ALLOWED - NOTICE OF ALLOWANCE MAILED - RELEASED TO OFFICE OF PUBLICATIONS

Location : 7560/ ALLOWED FILES 305-8495

Charge to Location : /

Potential Issue Ready**No****Requirements****Needed**

Drawing Required	Yes
Issue Fee Required	Yes
On Query	No
Under Signatory Review	No
PUBS Unmatched Paper	No
Unmatched Petition	No
Biotech	No
Petition	No
PCT	No
Needs Panel Review at TC	No
Under Quality Review	No

[Serial Info](#)[Contents](#)[Attorney Info](#)[Continuity Data](#)[Foreign Data](#)[Inventors](#)[Add](#)

(To Go BACK Use BACK Button on Your BROWSER Tool Bar)

Back to || [PUBS](#) || [PALM](#) || [OASIS](#) || [Home Page](#)

CARELLA, BYRNE, BAIN, GILFILLAN,
CECCHI, STEWART & OLSTEIN
6 Becker Farm Road
Roseland, New Jersey 07068
(201) 994-1700
(201) 994-1744 (FAX)

OPERATOR: JGMTIME COMPLETED: 6:25 PMEXT. NO.: 529DATE: 7/11/97OUR FILE NO.: 325800-449 (F189)

NAME

FIRM

Exmr J. Basham, P.D. AU1804

08/466,343 6/6/95
FAX NO.

703,308-0294

--ENTER IN FILE--

FROM: J.G. Mullins, Esq ^{RD 33,073}

Total Pages Including Transmittal Sheet

COMMENTS: I certify by the signature below that this
Coversheet and 6-page Supplemental Response are
being sent to the above telecopier number on
the above date. J.G. Mullins 7/11/97

IF YOU HAVE ANY PROBLEMS WITH THIS TRANSMISSION, OR DO NOT RECEIVE THE NUMBER OF
PAGES NOTED, PLEASE CONTACT THE FAX OPERATOR AT (201) 994-1700 (EXT. 211)

CONFIDENTIALITY NOTE: The documents accompanying this telecopy transmission contain information from the law firm of Carella, Byrne, Bain, Gilfillan, Cecchi, Stewart & Olstein, which is confidential and/or legally privileged. The information contained in this facsimile is intended only for the use of the individual named above and others who have been specifically authorized to receive it. If the one receiving it is not the intended recipient, you are hereby notified that any dissemination, distribution or copy of this communication is strictly prohibited. If you have received this telecopy in error, please notify us by telephone immediately so that we can arrange for the return of the original documents to us at once. Thank you.

The original of this document will be sent by:

☐ Ordinary Mail☐ Overnight Mail☐ Messenger☒ This will be the only form of
delivery of this Document

7560 415

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of : Yi Li and Steven M. Ruben
Serial No. : 08/466,343 Group: ~~1884~~ 1646
Filed : June 6, 1995 Examiner: ~~Basham, D.~~ Draper
For : HUMAN G-PROTEIN CHEMOKINE RECEPTOR HDGMR10
Docket No. : 325800-449 (PF189)

VIA TELECOPIER - ENTER IN FILE

EXPEDITED PROCEDURE - STATUS GRANTED BY PETITION
Assistant Commissioner for Patents
Box Amendment - No Fee Due
Washington, D.C. 20231

SUPPLEMENTAL RESPONSE TO OFFICE ACTION AND AMENDMENT

SIR:

This is in supplemental response to the fully responsive amendment filed by the undersigned on June 10, 1997. The amendment below is to further revise the claims directed to a process for making a polypeptide in view of an telephonic interview with the Examiner on July 11, 1997. No fees are believed to be necessary for filing of this paper, however please charge any necessary fees to Deposit Account No. 03-0678. A duplicate copy of this paper is enclosed.

AMENDMENTIn the Claims

38. (Twice Amended) A method for producing a polypeptide comprising expressing from the recombinant cell of claim 34 the

polypeptide encoded by said polynucleotide, wherein said polypeptide produced [comprises a polypeptide sequence which is at least 95% identical to the amino acid sequence of SEQ ID NO:2] when it has a sequence other than that of SEQ ID NO:2 will bind to a ligand which binds to a polypeptide having the sequence of SEQ ID NO:2.

39. (Twice Amended) A method for producing a polypeptide comprising expressing from the recombinant cell of claim 35 the polypeptide encoded by said polynucleotide, wherein said polypeptide produced [comprises a polypeptide sequence which is at least 95% identical to the amino acid sequence of SEQ ID NO:2] when it has a sequence other than that of SEQ ID NO:2 will bind to a ligand which binds to a polypeptide having the sequence of SEQ ID NO:2.

40. (Twice Amended) A method for producing a polypeptide comprising expressing from the recombinant cell of claim 36 the polypeptide encoded by said polynucleotide, wherein said polypeptide produced [comprises a polypeptide sequence which is at least 95% identical to the amino acid sequence of SEQ ID NO:2] when it has a sequence other than that of SEQ ID NO:2 will bind to a ligand which binds to a polypeptide having the sequence of SEQ ID NO:2.

41. (Twice Amended) A method for producing a polypeptide comprising expressing from the recombinant cell of claim 37 the

polypeptide encoded by said polynucleotide, wherein said polypeptide produced [comprises a polypeptide sequence which is at least 95% identical to the amino acid sequence of SEQ ID NO:2] when it has a sequence other than that of SEQ ID NO:2 will bind to a ligand which binds to a polypeptide having the sequence of SEQ ID NO:2.

Remarks

The above amendment is clerical in nature and merely clarifies the claims. Support for the above changes may be found on pages 23-24 of the specification, for example. Claims 21-54 are pending.

With regard to the utility of polypeptides produce by the process claims that are presently before the Examiner, such is believed to be clear in view of the above amendment and the original specification, particularly in view of the state of the art, for the following reasons.

The specification teaches how to utilize the polynucleotide according to SEQ ID NO:1 (and/or of the biological deposit) as a probe for chromosome identification and implicates the polypeptide(s) encoded thereby as being receptors involved in T-cell mediated diseases (see page 23, last full paragraph, for example). In addition, the polynucleotides having at least 95% sequence identity would be useful as probes to isolate the useful

polynucleotide of SEQ ID NO:1 from a composition comprising the polynucleotide of SEQ ID NO:1.

Thus, the starting materials for the process for producing the polypeptides are fully supported by the specification as indicated above. The only issue, therefore, is the utility of the polypeptides produced.

As presently claimed the polypeptides resulting from such processes as claimed in the present process claims, which polypeptides have a structure other than a polypeptide according to SEQ ID NO:2 will have the ability to bind a ligand that the polypeptide of SEQ ID NO:2 also has the ability to bind.

Page 23 of the specification, at the second full paragraph, highlights the significance of polypeptides that have the ability to also bind a ligand that would have bound to the polypeptide according to SEQ ID NO:2. Such polypeptides are useful for developing less than full-length or inactive polypeptides that will competitively bind the ligand and usurp the function of the polypeptide according to SEQ ID NO:2 or its equivalents.

Further, one of ordinary skill would fully appreciate in view of the state of the art taken in view the discussion at pages 23 and 24 of the specification, that such polypeptides would also be useful as scavengers for certain ligands that also bind the polypeptide according to SEQ ID NO:2. A process for isolating such

ligands from a mixture of cell fragments, for example, could readily use such polypeptides as scavengers for such ligands. Specific details for such scavenger process are well-known in the art and do not require any further particular details other than those at pages 23 and 24 for such processes to be appreciated and utilized.

Moreover, the G-coupled protein receptor and ligand art is well-developed and screens for identifying a ligand which binds to both the G-coupled protein receptor according to SEQ ID NO:2, for example, and a polypeptide produced by the above process claims exist. Therefore, such polypeptides would be useful for isolating ligands which bind to the G-coupled protein receptor according to the invention.

For the above stated reasons, in view of the above amendments, this case is believed to now be in condition for allowance. An early notice to that effect is urged.

The Examiner is invited to call the undersigned at the below number if any further action by applicant would expedite the examination of this application.

TELECOPIER TRANSMISSION CERTIFICATE	
Send date: <u>July 11</u> , 1997	
I hereby certify that this paper and the attachments hereto are being sent by telecopier transmission to 703-308-0294 on the date indicated above addressed to:	
Box Amendment - No Fee Due Assistant Commissioner for Patents Washington, DC 20331	
<u>J.G. Mullins</u> J.G. Mullins, Esq.	<u>7/11/97</u> Date

Respectfully submitted,



J.G. Mullins, Esq.

Reg. No. 33,073

CARELLA, BYRNE, BAIN,
GILFILLAN, CECCHI, STEWART
& OLSTEIN

Six Becker Farm Road

Roseland, NJ 07068

Tel. No.: (201) 994-1700

N:VHGS-AMD2.449